Evidence map›Paper›PMID 39583986›Full record

ArticleCase reports in hematology2024

High-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.

Daniel James, Simone Green, Stefano Molica, David Allsup

Abstract readCase Reports
In one paragraph

Article in Case reports in hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daniel JamesDepartment of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, UK.ORCID https://orcid.org/0000-0001-6458-2036
Simone GreenDepartment of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, UK.
Stefano MolicaDepartment of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, UK.
David AllsupDepartment of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecular response with imatinib, subsequently developed CLL, which necessitated the concomitant administration of ibrutinib.

Indexed as

chronic lymphocytic leukemiachronic myeloid leukemiatyrosine kinase inhibitors

Identifiers

PMID39583986
PMCPMC11584251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.